SEC Form 4 · accession 0000899243-17-016755
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jodie Pope Morrison
Director
Period of report
Jun 9, 2017
Accepted (ET)
Jun 20, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 9, 2017 | A | 10,000 | $0.00 | A | 10,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $6.56 | Jun 9, 2017 | A | 30,000 | A | Jun 9, 2018 | Jun 9, 2027 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020.
- F2Includes 10,000 shares of restricted stock.
- F3The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020.